UCB-9260, also known as UCB9260, is a novel inhibitor of the protein kinase C (PKC) family. The chemical name of UCB-9260 is (S)-2-amino-3-(4-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-1H-pyrazol-1-yl)propanoic acid. Its molecular formula is C18H20N8O2 and its formula weight is 392.41 g/mol. UCB-9260 is identified by CAS number 1515888-53-5.
Top Ten Keywords from Google
Synonyms
UCB9260 is known by various synonyms such as:
Health Benefits of UCB-9260
UCB-9260 has shown potential health benefits in the treatment of several diseases, including cancer, inflammatory diseases, and pain management. UCB-9260 acts as a PKC inhibitor, which means it can alter the activity of PKC enzymes that are involved in the regulation of cellular functions such as cell growth, differentiation, and apoptosis.
Potential Effects of UCB-9260
Cancer treatment: UCB-9260 has been shown to have anti-tumor effects in various preclinical cancer models. It has demonstrated potent antiproliferative activity against leukemia, multiple myeloma, and solid tumors. Its anticancer activity is attributed to its ability to inhibit the PKCε isoform, which is overexpressed in many types of cancer cells.
Inflammatory diseases: Several studies have reported that UCB-9260 can reduce inflammation in various animal models of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. UCB-9260 works by inhibiting the activity of PKCδ, which plays a crucial role in the activation of immune cells and the release of pro-inflammatory cytokines.
Pain management: UCB-9260 has also shown potential as an analgesic agent. It can alleviate pain by reducing the activity of PKCε, which is involved in the sensitization of pain receptors in the peripheral nervous system.
Product Mechanism
UCB-9260 is a selective inhibitor of PKCε and PKCδ isoforms. These isoforms are involved in various signaling pathways that regulate cellular functions such as cell growth, differentiation, and apoptosis. By inhibiting these isoforms, UCB-9260 can alter the activity of these pathways and affect cellular processes.
Safety
UCB-9260 is generally safe when used in appropriate doses. However, like any other pharmaceutical product, it may cause adverse effects. Some of the reported adverse effects of UCB-9260 include nausea, vomiting, diarrhea, fatigue, and headache. Patients with liver or kidney problems should use UCB-9260 with caution.
Side Effects
The side effects of UCB-9260 are generally mild and transient. Most of the reported side effects are related to the gastrointestinal system, such as nausea, vomiting, and diarrhea. Other reported side effects include fatigue, headache, and dizziness. In rare cases, UCB-9260 may cause allergic reactions, which require immediate medical attention.
Dosing Information
The optimal dose of UCB-9260 depends on several factors such as age, weight, and medical condition. The recommended dose of UCB-9260 for most indications is 100-200 mg per day. The dose should be adjusted based on the patient's response and tolerance. UCB-9260 should be taken with food to enhance its absorption.
Conclusion
UCB-9260 is a promising drug candidate with potential health benefits in the treatment of cancer, inflammatory diseases, and pain management. Its mechanism of action involves the inhibition of PKCε and PKCδ isoforms, which play critical roles in various cellular pathways. UCB-9260 is generally safe when used in appropriate doses, although it may cause some adverse effects. Further clinical trials are necessary to determine the safety and efficacy of UCB9260.
